PAI2, Recombinant, Human (Plasminogen Activator Inhibitor 2, PAI-2, Placental Plasminogen Activator Inhibitor, Monocyte Arg-serpin, Urokinase Inhibitor, Serpin B2, PLANH2, SERPINB2)

PAI-2 is an inhibitory serpin expressed mainly in keratinocytes, activated monocytes, and placental trophoblasts. It exists predominantly as a 47kD nonglycosylated intracellular protein which can be induced to be secreted as 60kD glycoprotein. The physiological relevance of this property, which is neither a consequence of any mutation in the PAI-2 gene nor associated with any known disorder, is still unclear. However, it appears that the formation of intracellular dormant polymers may be important for the controlled release of the inhibitor from PAI-2 producing cells. Plasma levels of PAI-2 are usually low or undetectable, except during pregnancy and in some forms of monocytic leukemia. Secretion of PAI-2 from the placenta normally occurs during the third trimester of pregnancy and accounts for the dramatic increase in PAI-2 levels (up to 250ng/ml), which are maintained at these levels until postpartum, and then rapidly decline. In addition to its vital role in protecting the placenta from degradation by uPA and/or uPA-activated proteases, PAI-2 has been shown to be essential for the prevention of metastatic spread of neck, lung and breast cancers. The beneficial effect of PAI-2 seen in these studies is presumed to stem from its ability to inhibit uPA-dependent cell dissemination. PAI-2 has also been reported to inhibit keratinocyte proliferation, and to participate in the innate immune response during viral infection. Recombinant human PAI-2 is a 415-residue nonglycosylated protein. Source: Recombinant protein corresponding to human PAI-2, expressed in E. coli. Biological Activity: Determined by its inhibitory effect against single chain tPA induced cleavage of a chromogenic substrate in Imidazole Buffer at 37 degrees C. Half maximal inhibition against 1ug/ml of single chain tPA was obtained at a concentration of 1ug/ml. Endotoxin Level: <0.1ng/ug (1EU/ug) AA Sequence: MEDLCVANTL FALNLFKHLA KASPTQNLFL SPWSISSTMA MVYMGSRGST EDQMAKVLQF NEVGANAVT PMTPENFTSC GFMQQIQKGS YPDAILQAQA ADKIHSSFRS LSSAINASTG N YLLESVNK LFGEKSASFR EEYIRLCQKY YSSEPQAVDF LECAEEARKK INSWVKTQTK GK IPNLLPE GSVDGDTRMV LVNAVYFKGK WKTPFEKKLN GLYPFRVNSA QRTPVQMMYL REK LNIGYI EDLKAQILEL PYAGDVSMFL LLPDEIADVS TGLELLESEI TYDKLNKWTS KDKM AEDEV EVYIPQFKLE EHYELRSILR SMGMEDAFNK GRANFSGMSE RNDLFLSEVF HQAMV DVNE EGTEAAAGTG GVMTGRTGHG GPQFVADHPF LFLIMHKITN CILFFGRFSS P Storage and Stability: Lyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile buffer or dH2O. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.